← Leaderboards
Razelle Kurzrock
University Of Texas Md Anderson Can Ctr
$10,423,704
Attributed
$14,195,782
Total exposure
8
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,195,782 · 8
By mechanism
U01$4,857,269 · 1
P30$2,987,563 · 2
K12$2,694,731 · 1
UG1$2,370,709 · 1
R21$990,510 · 2
K30$295,000 · 1
Top collaborators
- Robert C Bast5 shared
- Robert M. Chamberlain5 shared
- William H Bradley4 shared
- Elizabeth M Gore4 shared
- Stuart J Wong4 shared
- Tina Wf Yen4 shared
- Timothy S Fenske2 shared
- Mehdi Hussain Hamadani2 shared
Most similar at University Of Texas Md Anderson Can Ctr
Same institution · by research overlap
- Robert C Bast$38,086,401
- Margaret R Spitz$17,223,484
- Paul J Chiao$8,649,694
- Benoit De Crombrugghe$14,777,483
- Robert M. Chamberlain$13,499,222
Others in their field
Top investigators on “Clinical Trials”
- Lawrence Corey · Fred Hutchinson Cancer Center$824,102,536
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$622,583,125
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,008,718
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$504,273,077
Research focus
Clinical TrialsMalignant NeoplasmsResearch PersonnelClinical ResearchProgramsCancer TherapyResourcesScientistPublicationsCancer CenterFacultyLaboratoriesBasic ScienceBaseOperationMentorsResearch InfrastructureData ManagementInfrastructureTrainingBloodGrantEnsureTranslational Research
Grant awards (31)
MCW NCTN Lead Academic Participating Site Administrative Supplement$569,544
UG1 · FY2025 · CA
MCW NCTN Lead Academic Participating Site$609,494
UG1 · FY2024 · CA
MCW NCTN Lead Academic Participating Site$596,655
UG1 · FY2023 · CA
Clinical Protocol and Data Management$541,277
P30 · FY2023 · CA · contact PI
MCW NCTN Lead Academic Participating Site$595,016
UG1 · FY2022 · CA
Clinical Protocol and Data Management$543,488
P30 · FY2022 · CA · contact PI
Clinical Protocol and Data Management$540,992
P30 · FY2021 · CA · contact PI
Clinical Protocol and Data Management$578,464
P30 · FY2020 · CA · contact PI
Clinical Protocol and Data Management$539,279
P30 · FY2019 · CA · contact PI
Paul Calabresi Clinical Oncology Award$251,041
K12 · FY2014 · CA
Paul Calabresi Clinical Oncology Award$650,081
K12 · FY2013 · CA
CLINICAL TRIALS$244,063
P30 · FY2013 · CA · contact PI
Paul Calabresi Clinical Oncology Award$658,054
K12 · FY2012 · CA
Paul Calabresi Clinical Oncology Award$649,162
K12 · FY2011 · CA
Phase I Studies of Targeted Anti-Cancer Therapies$594,886
U01 · FY2011 · CA · contact PI
Phase I Studies of Targeted Anti-Cancer Therapies$613,776
U01 · FY2010 · CA · contact PI
Paul Calabresi Clinical Oncology Award$486,393
K12 · FY2010 · CA
Phase I Studies of Targeted Anti-Cancer Therapies$539,134
U01 · FY2009 · CA · contact PI
Phase I Studies of Targeted Anti-Cancer Therapies$647,881
U01 · FY2008 · CA · contact PI
Phase I Studies of Targeted Anti-Cancer Therapies$529,795
U01 · FY2007 · CA · contact PI
Phase I Studies of Targeted Anti-Cancer Therapies$529,725
U01 · FY2006 · CA · contact PI
Curriculum for Patient-Oriented Clinical Cancer Research$45,000
K30 · FY2006 · RR · contact PI
Phase I Studies of Targeted Anti-Cancer Therapies$526,608
U01 · FY2005 · CA
Curriculum for Patient-Oriented Clinical Cancer Research$250,000
K30 · FY2005 · RR
Exploratory Trial of Curcumin in Pancreatic Cancer$203,850
R21 · FY2005 · CA
Phase I Studies of Targeted Anti-Cancer Therapies$361,094
U01 · FY2004 · CA
Exploratory Trial of Curcumin in Pancreatic Cancer$203,850
R21 · FY2004 · CA
Phase I Studies of Targeted Anti-Cancer Therapies$496,440
U01 · FY2003 · CA
Phase I Studies of Targeted Anti-Cancer Therapies$17,930
U01 · FY2003 · CA
Farnesyltransferase Inhibitor Therapy for Myelodysplasia$287,910
R21 · FY2002 · CA
Farnesyltransferase Inhibitor Therapy for Myelodysplasia$294,900
R21 · FY2001 · CA